Pfizer And GSK Call For Early Risk Tests; Sign Of Further Vioxx Fallout?
Executive Summary
GlaxoSmithKline will launch a risk assessment program that will allow company researchers to more rapidly recognize safety signals
You may also be interested in...
Bextra Withdrawn At FDA’s Request; Pfizer Holds Out Hope For Return
Pfizer will have to show a "unique" benefit associated with Bextra in order to justify a return to the U.S. market, FDA Office of New Drugs Director John Jenkins said during an April 7 media conference call announcing the withdrawal of the COX-2 inhibitor
Zeldox Bold Interaction Warning, Not Black Box, Needed For QTc - Committee
Labeling for Pfizer's Zeldox (ziprasidone) should clearly warn against combination use with other drugs that may prolong the QTc interval, but a black box may not be necessary, FDA's Psychopharmacological Drugs Advisory Committee suggested July 19.
Pfizer Discussing Trovan Labeling With FDA; Hepatic Injuries "Unpredictable"
The unpredictability of liver injuries associated with use of Trovan (trovafloxacin) is the challenge facing Pfizer and the probable point-of-departure for discussions with FDA.